Study of MOC31-PE in Antigen Positive Carcinomas
Primary Purpose
Carcinoma
Status
Completed
Phase
Phase 1
Locations
Norway
Study Type
Interventional
Intervention
MOC31-PE
Sponsored by

About this trial
This is an interventional treatment trial for Carcinoma focused on measuring MDT and DLT
Eligibility Criteria
Inclusion Criteria:
- Histologically confirm epithelial carcinoma, verified to be positive for the targeting antigen(Ep-CAM/epithelial glyco protein 2)according to the criteria given below.
- Tumor specimens verified to be positive for the targeting antibody,i.e.EGP2 positive (MOC31) by immunocytochemical or histochemical staining.
- Signed written informed consent
- Patients with no clinically symptomatic central nervous system (CNS) involvement.
- Both gender, age 18 -75 years old.
- Life expectancy of at least 3 months
- Eastern Cooperative Oncology Group (ECOG) Performance status 0-2
- Adequate hematologic, renal and hepatic function defined as: Neutrophils > 1.5 x 10^9/L;Platelets > 100 x 10^9/L; Creatinine < 120 umol/L; Total bilirubin within normal range. Liver enzymes (ALAT and ASAT <2.5 UNL: alkaline phosphatase < 1.5 UNL and yGT < 1.5 UNL).
- Coagulation parameters (pT, PTT) within normal range.
Exclusion Criteria:
- No medical history of Hepatitis B or C infection
- Patients must have no ECG abnormalities
- Patients must not be HIV positive
- Female premenopausal patients should not be pregnant (must have a negative pregnancy test prior to inclusion) and should not be lactating.
- Patients must use effective contraception if of reproductive potential.
- Prior chemotherapy and/or radiation should be completed for at least 4 weeks prior to study enrolment
Sites / Locations
- The Norwegian Radium Hospital, Department of Clinical Cancer Research
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
MOC31-PE
Arm Description
Outcomes
Primary Outcome Measures
The documentation of the Maximum Tolerated Dose (MID)
The identification of the dose limiting toxicity (DLT)
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01061645
Brief Title
Study of MOC31-PE in Antigen Positive Carcinomas
Official Title
Phase I Study of MOC31-PE in Antigen Positive Carcinomas
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Completed
Study Start Date
September 2010 (undefined)
Primary Completion Date
February 2012 (Actual)
Study Completion Date
February 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Oslo University Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Immunotoxins (ITs), monoclonal antibodies conjugated to plant or bacterial toxins, have been extensively investigated for their possible use as anti-tumor agents although not in carcinoma patients with minimal residual disease. Various ITs have been tested in early clinical trials and recent studies demonstrate anti-tumor activity of IT treatment in patients with glioblastoma and different solid tumors. Systemic treatment with immunotoxins directed against carefully selected epithelial cell surface molecules may have a potential for eradicating also dormant metastatic tumor cells, as their action is independent of cell proliferation. The effector moieties of the IT used here, the Pseudomonas exotoxin A (PE), inhibits protein synthesis in eukaryotic cells by catalytic inactivation (ribosylation) of elongation factor 2 in the ribosome complex.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Carcinoma
Keywords
MDT and DLT
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
20 (Actual)
8. Arms, Groups, and Interventions
Arm Title
MOC31-PE
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
MOC31-PE
Intervention Description
Immunotoxines
Primary Outcome Measure Information:
Title
The documentation of the Maximum Tolerated Dose (MID)
Time Frame
2 years
Title
The identification of the dose limiting toxicity (DLT)
Time Frame
2 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Histologically confirm epithelial carcinoma, verified to be positive for the targeting antigen(Ep-CAM/epithelial glyco protein 2)according to the criteria given below.
Tumor specimens verified to be positive for the targeting antibody,i.e.EGP2 positive (MOC31) by immunocytochemical or histochemical staining.
Signed written informed consent
Patients with no clinically symptomatic central nervous system (CNS) involvement.
Both gender, age 18 -75 years old.
Life expectancy of at least 3 months
Eastern Cooperative Oncology Group (ECOG) Performance status 0-2
Adequate hematologic, renal and hepatic function defined as: Neutrophils > 1.5 x 10^9/L;Platelets > 100 x 10^9/L; Creatinine < 120 umol/L; Total bilirubin within normal range. Liver enzymes (ALAT and ASAT <2.5 UNL: alkaline phosphatase < 1.5 UNL and yGT < 1.5 UNL).
Coagulation parameters (pT, PTT) within normal range.
Exclusion Criteria:
No medical history of Hepatitis B or C infection
Patients must have no ECG abnormalities
Patients must not be HIV positive
Female premenopausal patients should not be pregnant (must have a negative pregnancy test prior to inclusion) and should not be lactating.
Patients must use effective contraception if of reproductive potential.
Prior chemotherapy and/or radiation should be completed for at least 4 weeks prior to study enrolment
Facility Information:
Facility Name
The Norwegian Radium Hospital, Department of Clinical Cancer Research
City
Oslo
ZIP/Postal Code
NO-0310
Country
Norway
12. IPD Sharing Statement
Learn more about this trial
Study of MOC31-PE in Antigen Positive Carcinomas
We'll reach out to this number within 24 hrs